PharmaCorp RxTSXV:PCRX +1.96%36 EBITDA Margin % is 7.26% as of Mar. 2026. GuruFocus rates TSXV:PCRX with a GF Score™ of 36/100. The stock has 2 warning signs investors should review. Among 668 Healthcare Providers & Services companies, PharmaCorp Rx ranks worse than 72.9% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. PharmaCorp Rx's EBITDA for the
three
months ended in Mar. 2026 was C$0.52 Mil. PharmaCorp Rx's Revenue for the
three
months ended in Mar. 2026 was C$7.19 Mil. Therefore, PharmaCorp Rx's EBITDA margin for the quarter that ended in Mar. 2026 was 7.26%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
PharmaCorp Rx EBITDA Margin % Related Terms
PharmaCorp Rx EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for PharmaCorp Rx's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, PharmaCorp Rx's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaCorp Rx EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, PharmaCorp Rx's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where PharmaCorp Rx's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmaCorp Rx (TSXV:PCRX) has a EBITDA Margin % of 7.26% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PharmaCorp Rx and its competitors. According to the industry distribution chart, PharmaCorp Rx ranks #487 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 72.9%.
Is PharmaCorp Rx's EBITDA Margin % too high?
PharmaCorp Rx's current EBITDA Margin % is 7.26%. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. PharmaCorp Rx's value of 7.26% is 28.9% below this industry median. Based on the distribution chart, PharmaCorp Rx ranks #487 out of 668 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, PharmaCorp Rx has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCorp Rx's EBITDA Margin % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, PharmaCorp Rx ranks #487 out of 668 companies for EBITDA Margin %. This places PharmaCorp Rx in the lower half of its industry. The industry median EBITDA Margin % is 10.21. PharmaCorp Rx's value of 7.26% is 28.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PharmaCorp Rx's current EBITDA Margin % of 7.26% is 28.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PharmaCorp Rx and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmaCorp Rx's current EBITDA Margin % is 7.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCorp Rx stock overvalued right now?
PharmaCorp Rx (TSXV:PCRX) has a current EBITDA Margin % of 7.26%. The current EBITDA Margin % is 7.26% and 28.9% below the Healthcare Providers & Services industry median of 10.21. PharmaCorp Rx's overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For PharmaCorp Rx (TSXV:PCRX), the current EBITDA Margin % is 7.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PharmaCorp Rx Inc operates three PharmaChoice bannered pharmacies in Canada and will continue to acquire PharmaChoice Canada-branded pharmacies as it come to market in conjunction with its strategic alliance agreement with PharmaChoice Canada. The company will also acquire independently owned non-PharmaChoice Canada-bannered pharmacies in Canada, and thereafter, continue to operate such acquired pharmacies under a PharmaChoice Canada banner.
36GF Score
Get the complete analysis for TSXV:PCRX
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:PCRX has been successfully added to your 
